Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probucol in Reducing the Risk of Recurrent Stroke
NCT06225752Phase 3Recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- Jun 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and Transient Ischemic Attack (TIA) comparing Probucol Group with Placebo Probucol Group (2 arms). Primary endpoint: Recurrent stroke event at 1 year. Started Jun 2024; status: recruiting.
02
Drugs
probucol
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06225752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225752.